Test a new country before you bet on it.

People who live in your target country and have the problem your product addresses: the ones who would use it if it existed there. They are volunteers, recruited through local communities (patient groups, associations, online groups), not drawn from your network, so nobody is being polite. They are not paid. That is the point: with nothing to gain but the product itself, their usage is a real signal. They know which product they are testing.

A minimum of 20 qualified volunteers per country. What the plan commits to is that panel: who they are, how they are recruited, and how we support them through the eight weeks. Usage hours are measured and reported week by week. They are the result of the test, not a promise.

Typically 12 to 13 weeks end to end: one week to scope and sign off the plan, two to three weeks to recruit, eight weeks of usage, then the report. Eight weeks of usage is the minimum to see habit rather than curiosity. Comparing several countries runs on the same calendar, in parallel.

With volunteers, drop-off is a result, not a delivery failure. If people in that country stop using your product in week three, that is exactly what you need to know before launching, and the report says who left, when, and what they said. What Eldwin guarantees is the panel: at least 20 qualified volunteers per country, recruited and supported from the first day to the last. The hours they put in are measured, not promised.

Each tester gives explicit, informed consent for each test. Data is pseudonymised from day one: you receive usage data and the panel's make-up (ages, cities, habits), never identities. Every test is designed to run under GDPR rules for health data, with a data protection impact assessment and a processing agreement signed with you. The details are agreed in the one-page plan; our privacy notice sets out the rest.

Europe, North America and Asia-Pacific, plus Israel. The full list is in the Markets grid above. Tests run in both directions: a European product tested in Asia, or an Asian product tested in Europe. If your country isn't listed, ask: you'll get a straight answer.

A report with three parts: what people did (usage data over the eight weeks, retention, the features they came back to), what they said (structured feedback, in their words), and a reading: go, adjust or stop, with the reasons. For a multi-country test, the same report per country plus a ranked deployment order. Then a call to walk through it.

A market study tells you about the market. A panel tells you what people think in a one-hour session. A soft launch tells you what a user costs to acquire, not whether they stay. A market test tells you what people do with your product over eight weeks, in the country you're targeting. Market test vs panel · Market test vs soft launch.

No. A clinical trial measures medical safety and efficacy under regulatory supervision; a market test measures whether people in a given country adopt and keep using your product. The full comparison is here.

Thirty minutes on the market you're looking at, what you need to learn there, and whether a test makes sense now. If it doesn't, we say so. If it does, you receive a one-page test plan to sign off before anything starts.